PURPOSE: To determine if ifosfamide-based chemotherapy (IF) offers a survival benefit to adult patients with primary extremity synovial sarcoma. PATIENTS AND METHODS: Prospectively collected patient data from 2 institutions was used to identify all adult patients (>or=16 years) with >or=5 cm, deep, primary, extremity, synovial sarcoma that underwent surgical treatment of cure from 1990 to 2002. A total of 101 patients were identified and the median follow-up for survivors was 58 months. Clinical, pathologic, and treatment variables were analyzed for disease-specific survival (DSS), distant recurrence-free survival (DRFS), and local recurrence-free survival (LRFS). RESULTS: Sixty-eight (67%) patients were treated with IF and 33 (33%) patients received no chemotherapy (NoC) for the primary tumor. The characteristics of the IF-treated patients [median tumor size = 7.2 cm; monophasic n = 46 (68%)] were similar to NoC patients [median tumor size = 7 cm; monophasic n = 23 (70%)]. The 4-year DSS of the IF-treated patients was 88% compared with 67% for the NoC patients (P = 0.01). Smaller size (HR = 0.3 per 5-cm decrease, P < 0.0001) and treatment with IF (HR = 0.3 compared with NoC, P = 0.007) were independently associated with an improved DSS. Treatment with IF was independently associated with an improved DRFS (HR = 0.4, P = 0.03) but not associated with an improved LRFS (P = 0.39). CONCLUSION: Ifosfamide-based chemotherapy was associated with an improved DSS in adult patients with high-risk, primary, extremity, synovial sarcoma and should be considered in the treatment of such patients.
PURPOSE: To determine if ifosfamide-based chemotherapy (IF) offers a survival benefit to adult patients with primary extremity synovial sarcoma. PATIENTS AND METHODS: Prospectively collected patient data from 2 institutions was used to identify all adult patients (>or=16 years) with >or=5 cm, deep, primary, extremity, synovial sarcoma that underwent surgical treatment of cure from 1990 to 2002. A total of 101 patients were identified and the median follow-up for survivors was 58 months. Clinical, pathologic, and treatment variables were analyzed for disease-specific survival (DSS), distant recurrence-free survival (DRFS), and local recurrence-free survival (LRFS). RESULTS: Sixty-eight (67%) patients were treated with IF and 33 (33%) patients received no chemotherapy (NoC) for the primary tumor. The characteristics of the IF-treated patients [median tumor size = 7.2 cm; monophasic n = 46 (68%)] were similar to NoCpatients [median tumor size = 7 cm; monophasic n = 23 (70%)]. The 4-year DSS of the IF-treated patients was 88% compared with 67% for the NoCpatients (P = 0.01). Smaller size (HR = 0.3 per 5-cm decrease, P < 0.0001) and treatment with IF (HR = 0.3 compared with NoC, P = 0.007) were independently associated with an improved DSS. Treatment with IF was independently associated with an improved DRFS (HR = 0.4, P = 0.03) but not associated with an improved LRFS (P = 0.39). CONCLUSION:Ifosfamide-based chemotherapy was associated with an improved DSS in adult patients with high-risk, primary, extremity, synovial sarcoma and should be considered in the treatment of such patients.
Authors: S Frustaci; F Gherlinzoni; A De Paoli; M Bonetti; A Azzarelli; A Comandone; P Olmi; A Buonadonna; G Pignatti; E Barbieri; G Apice; H Zmerly; D Serraino; P Picci Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: J M Coindre; P Terrier; N B Bui; F Bonichon; F Collin; V Le Doussal; A M Mandard; M O Vilain; J Jacquemier; H Duplay; X Sastre; C Barlier; M Henry-Amar; J Macé-Lesech; G Contesso Journal: J Clin Oncol Date: 1996-03 Impact factor: 44.544
Authors: Fritz C Eilber; Frederick R Eilber; Jeffery Eckardt; Gerald Rosen; Elyn Riedel; Robert G Maki; Murray F Brennan; Samuel Singer Journal: Ann Surg Date: 2004-10 Impact factor: 12.969
Authors: Thomas F DeLaney; Ira J Spiro; Herman D Suit; Mark C Gebhardt; Francis J Hornicek; Henry J Mankin; Andrew L Rosenberg; Daniel I Rosenthal; Fariba Miryousefi; Marcus Ancukiewicz; David C Harmon Journal: Int J Radiat Oncol Biol Phys Date: 2003-07-15 Impact factor: 7.038
Authors: T Brodowicz; E Schwameis; J Widder; G Amann; C Wiltschke; M Dominkus; R Windhager; P Ritschl; R Pötter; R Kotz; C C Zielinski Journal: Sarcoma Date: 2000
Authors: Toshinori Sakai; Ramez N Eskander; Yi Guo; Kap Jung Kim; Jason Mefford; Justin Hopkins; Nitin N Bhatia; Xiaolin Zi; Bang H Hoang Journal: J Orthop Res Date: 2011-12-29 Impact factor: 3.494
Authors: Jared J Barrott; Ju-Fen Zhu; Kyllie Smith-Fry; Asia M Susko; Dakota Nollner; Lance D Burrell; Amir Pozner; Mario R Capecchi; Jeffrey T Yap; Lisa A Cannon-Albright; Xingming Deng; Kevin B Jones Journal: Mol Cancer Res Date: 2017-08-29 Impact factor: 5.852
Authors: Matthias R Benz; Johannes Czernin; Martin S Allen-Auerbach; William D Tap; Sarah M Dry; David Elashoff; Kira Chow; Vladimir Evilevitch; Jeff J Eckardt; Michael E Phelps; Wolfgang A Weber; Fritz C Eilber Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531